DGAP-News

MOLOGEN presents first anti-tumor data of the product candidate and TLR9 agonist EnanDIM(R) in a murine tumor model

DGAP-News: MOLOGEN AG / Key word(s): Conference
MOLOGEN presents first anti-tumor data of the product candidate and TLR9
agonist EnanDIM(R) in a murine tumor model

12.09.2016 / 09:16
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE N 14 / 2016 of 09/12/2016

MOLOGEN presents first anti-tumor data of the product candidate and TLR9
agonist EnanDIM(R) in a murine tumor model

Berlin, 12 September 2016 - The biotech company MOLOGEN AG (ISIN
DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today
first preliminary data on its EnanDIM(R) technology in a murine tumor
model. EnanDIM(R) is a new family of TLR9 agonists and so-called Immune
Surveillance Reactivators (ISR). The pre-clinical in vivo data shows that
EnanDIM(R) can reduce tumor growth and thus prolong survival. It has been
shown previously that EnanDIM(R) molecules broadly activate immune cells in
vitro and revealed no signs of toxicity after the administration of maximal
feasible doses in vivo. These data constitute the next pre-clinical step
towards a clinical development program of EnanDIM(R) in the treatment of
cancer.

"This is the next important step for our promising new generation TLR9
agonist EnanDIM(R). For the first time we observed reduced tumor growth in
a murine model. These results strongly support the pre-clinical development
of our EnanDIM(R) compounds", said Dr Mariola Söhngen, CEO of MOLOGEN AG.

MOLOGEN's new strategy program "Next Level", presented beginning of June
2016, includes a clear concentration on the lead product, the cancer
immunotherapy lefitolimod and next-generation molecules EnanDIM(R).

EnanDIM(R) (Enantiomeric, DNA-based, ImmunoModulator), as a new generation
of immunomodulators and so-called Immune Surveillance Reactivators (ISR),
belongs to the class of TLR9 agonists and represents one of MOLOGEN's
follow-up compounds to lefitolimod (MGN1703) exhibiting longer patent
protection, and a one-step production process as well as an
immunomodulatory pattern dependent on the specific EnanDIM(R) molecule.

The EnanDIM(R) molecules consist entirely of natural DNA, as is also the
case with lefitolimod (MGN1703). The main difference between MOLOGEN's two
ISR families is their molecule structure. Whereas lefitolimod (MGN1703) is
dumbbell-shaped and covalently-closed, EnanDIM(R) molecules have a linear
structure. However, as with lefitolimod (MGN1703), due to its specific